RemeGen Co. Ltd. Class A
688331
株式のランク
#2413
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
株価
$14.49
時価総額
$8.11B
変化（1日）
2.99%
変化（1年）
9.18%
国
CN
取引 RemeGen Co. Ltd. Class A (688331)
カテゴリー
Healthcare
RemeGen Co. Ltd. Class A（688331）のP/B比率
October 2026 時点のP/B比率 TTM: 6.73
RemeGen Co. Ltd. Class A の最新の財務報告および株価によると、現在のP/B比率（TTM）は 6.73 です。2023 年末時点でのP/B比率は 9.58 でした。
RemeGen Co. Ltd. Class A の P/B 比率の履歴（2018 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 6.73 | -17.42% |
| 2024 | 8.15 | -14.93% |
| 2023 | 9.58 | 16.11% |
| 2022 | 8.25 | 42.80% |
| 2021 | 5.78 | 24.56% |
| 2020 | 4.64 | -105.51% |
| 2019 | -84.22 | 114.76% |
| 2018 | -39.22 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.251 | -7.12% |
US
|
|
| 13.2547 | 96.95% |
US
|
|
| 4.208 | -37.47% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -8.14% |
NL
|
